Digital Biomarkers Market

The report "Digital Biomarkers Market by Product (Wearables, Sensors, Mobile-based Applications), Type (Physiological, Idiosyncratic), Disease Indication (Autoimmune, Cardiovascular), End User (Pharma & Biotech Companies, Medtech Companies) – Global Forecast to 2030 ", is projected to reach USD 15.60 billion by 2030 from USD 6.30 billion in 2025, at a CAGR of 19.9% during the forecast period.

Browse 408 market data Tables and 56 Figures spread through 568 Pages and in-depth TOC on "Digital Biomarkers Market by Product (Wearables, Sensors, Mobile-based Applications), Type (Physiological, Idiosyncratic), Disease Indication (Autoimmune, Cardiovascular), End User (Pharma & Biotech Companies, Medtech Companies) – Global Forecast to 2030 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/digital-biomarker-market-7725399.html

The digital biomarkers market is experiencing growth, driven by several key factors, including the expansion of wearables & remote monitoring devices and the integration of advanced analytics & AI.

Cardiovascular disorders segment accounted for the largest share of the digital biomarkers market, by disease indication, in 2024.

Cardiovascular disorders accounted for the largest share of the digital biomarkers market by disease indication, supported by the early clinical validation and widespread adoption of mobile- and wearable-based cardiac monitoring technologies. Digital biomarkers derived from ECG signals, heart rate variability, and rhythm analysis have become integral to the detection, monitoring, and management of conditions such as atrial fibrillation, arrhythmias, and other cardiac abnormalities. Strong clinical acceptance, regulatory clearances for software-based cardiac biomarkers, and integration into remote patient monitoring and telecardiology workflows have further reinforced cardiovascular applications as the dominant indication segment, particularly across hospital, outpatient, and home-based care settings.

In 2024, the mobile-based application segment is projected to register the fastest growth in the digital biomarkers market, by product.

Mobile-based applications represented the fastest-growing product segment in the digital biomarkers market, driven by their ability to leverage smartphones for continuous, real-world data collection at scale. These applications enable passive and active capture of physiological, behavioral, and cognitive data, supporting longitudinal disease monitoring, early detection, and assessment of treatment response without dedicated hardware. Rapid adoption has been supported by high smartphone penetration, improved sensor fidelity, regulatory acceptance of software-based biomarkers, and seamless integration with cloud analytics and clinical workflows, particularly across cardiology, neurology, and mental health use cases.

North America accounted for the largest share of the digital biomarkers market in 2024.

The market for digital biomarkers is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share of the digital biomarkers market, reflecting its strong base of academic medical centers, integrated health systems, and digital health innovators that have rapidly adopted mobile-, wearable-, and software-based biomarker technologies. The region benefits from favorable reimbursement frameworks for remote patient monitoring, early regulatory acceptance of software-as-a-medical-device (SaMD), and major government and payer initiatives supporting digital health adoption. In addition, high levels of pharma and biotech investment in biomarker-enabled clinical trials, real-world evidence generation, and decentralized study designs continue to reinforce North America’s leading position in global digital biomarker revenues.

Key players in the digital biomarkers market include Ametris (US), AliveCor (US), BioSensics (US), Mindstrong Health (US), iCOMETRIX (Belgium), BACtrack (US), AccuLabs (US), and AtCor Medical (Australia).

Don’t miss out on business opportunities in Digital Biomarkers Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/